Kaiser Family Foundation/ Harvard School of Public Health Medicare Prescription Drug Survey
A new survey by the Kaiser Family Foundation and Harvard School of Public Health examines public opinion on the current Medicare prescription drug debate.
View the Latest: Prescription Drugs
Filter
-
-
How Can Trump Administration Regulations Be Reversed?
Issue BriefWith the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.
-
Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines
Issue BriefAs the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also requires two doses, to shed light on this potential challenge of the leading COVID-19 vaccine candidates.
-
Strategies To Lower Drug Costs Top the Public’s Health Priorities for Congress
News ReleaseAgainst the backdrop of public concern about inflation and rising gas prices, proposals to lower what people pay out-of-pocket for drugs tops the public’s list of health care priorities for Congress, a new KFF Health Tracking Poll finds. Most (55%) of the public say inflation is the biggest problem facing the country.
-
Executive Actions to Address Prescription Drug Affordability in the U.S.
Event Date:EventOn May 23, 2022, a panel of experts joined series moderator Larry Levitt in a 45-minute discussion exploring the drivers of rising drug prices and potential administrative actions to address them.
-
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending
News ReleaseTwenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis.
-
The Public and Prescription Drugs
Other PostPrescription drugs have become an integral part of medical practice - they help keep people healthy and save lives. But rising prescription drug costs have placed a growing burden on consumers, employers, and public programs. The issue of drug coverage for seniors under Medicare has moved to center stage in the Presidential election.
-
The Current Medicare Prescription Drug Debate: Briefing Charts
ReportThese briefing charts provide background information on prescription drug use and spending among the Medicare population, recent survey data on employers' likely reaction to a Medicare drug benefit, an overview of the proposals for prescription drug coverage passed by the House and Senate at the end of June 2003, and a summary of the key…
-
Prescription Drug Trends: A Chartbook Update
ReportThis November 2001 Chartbook updates data from last year's chartbook, including information about prescription drug coverage, expenditures and prices, utilization, drug promotion, and the pharmaceutical industry.
-
Pharmacy Plus Waivers: Trade Offs Between Expanding Rx Coverage and Global Caps in Medicaid
Issue BriefThe Kaiser Commission on Medicaid and the Uninsured has been monitoring the development of the Pharmacy Plus waiver initiated by the Bush Administration in 2002 and tracking the states that have pending or approved plans.